- PackSize
- 50ug/100ug
- Target
- CD1
- Reactivity
- Human
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Chimeric
- Isotype
- IgG1-kappa-lambda
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% purity as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
- Species
- --
- Gene ID-1
- Q15116
- Uniprot
- --
- Background
- Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.<br>• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870<br/>• PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations., PMID:30888929<br/>• The diverse functions of the PD1 inhibitory pathway., PMID:28990585<br/>• PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy., PMID:30191996<br/>• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845<br/>• PD-1 expression and clinical PD-1 blockade in B-cell lymphomas., PMID:29118007<br/>• Overcoming T cell exhaustion in infection and cancer., PMID:25797516<br/>• Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker., PMID:32875727<br/>• Tumor Mutational Burden and Response Rate to PD-1 Inhibition., PMID:29262275<br/>• PD-L1., PMID:29097600<br/>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --